Acetyl-L-carnitine and α-lipoic acid: Possible neurotherapeutic agents for mood disorders?

Expert Opinion on Investigational Drugs

Volumn 17, Issue 6, 2008, Pages 827-843

  Soczynska, Joanna K ^a,b   Kennedy, Sidney H ^a,b,c   Chow, Cindy S M ^b   Woldeyohannes, Hanna O ^b   Konarski, Jakub Z ^a,b   McIntyre, Roger S ^a,b,c  

^a UNIVERSITY OF TORONTO   (Canada)

^b UNIVERSITY HEALTH NETWORK   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

Author keywords

Bipolar disorder; Cognition; Depression; L carnitine; Lipoic acid; Memory; Neuroprotection

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ALPHA TOCOPHEROL; AMISULPRIDE; ASCORBIC ACID; CARNITINE; CHOLINESTERASE INHIBITOR; DONEPEZIL; GAMMA LINOLENIC ACID; GLUCOCORTICOID; LEVACECARNINE; MIANSERIN; PLACEBO; RIVASTIGMINE; SELEGILINE; THIOCTIC ACID;

ALZHEIMER DISEASE; AMYLOIDOSIS; ANTIOXIDANT ACTIVITY; BIPOLAR DISORDER; BLOOD BRAIN BARRIER; CENTRAL NERVOUS SYSTEM DISEASE; CLINICAL TRIAL; COGNITIVE DEFECT; COMBINATION CHEMOTHERAPY; DEGENERATIVE DISEASE; DEMENTIA; DIABETES MELLITUS; DISORDERS OF MITOCHONDRIAL FUNCTIONS; DRUG ABSORPTION; DRUG EFFICACY; DRUG MEGADOSE; DRUG METABOLISM; DYSTHYMIA; ENERGY METABOLISM; GASTROINTESTINAL SYMPTOM; HUMAN; INFLAMMATION; MAJOR DEPRESSION; MONOTHERAPY; MOOD DISORDER; NAUSEA; NEUROPROTECTION; NONHUMAN; OXIDATIVE STRESS; PATHOPHYSIOLOGY; REVIEW; VERTIGO; VOMITING;

ACETYLCARNITINE; AGED; ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIOXIDANTS; CARNITINE; CLINICAL TRIALS AS TOPIC; COGNITION DISORDERS; DRUG EVALUATION, PRECLINICAL; ENERGY METABOLISM; FEMALE; HUMANS; IMMUNOLOGIC FACTORS; MALE; MICE; MIDDLE AGED; MITOCHONDRIA; MOOD DISORDERS; NEURODEGENERATIVE DISEASES; NEUROPROTECTIVE AGENTS; OXIDATIVE STRESS; PSYCHOTROPIC DRUGS; RATS; RATS, WISTAR; THIOCTIC ACID;

EID: 45749114952     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543784.17.6.827     Document Type: Review

References (103)

1. Kessler R. Comorbidity of unipolar and bipolar depression with other psychiatric disorders in a general population survey. In: editors, Comorbidity in affective disorders. New York: Marcel Dekker, Inc.; 1999. p. 1-25
2. Kessler RC, Rubinow DR, Holmes C, et al. The epidemiology of DSM-III-R bipolar I disorder in a general population survey. Psychol Med 1997;27:1079-89
3. MacQueen GM, Galway TM, Hay J, et al. Recollection memory deficits in patients with major depressive disorder predicted by past depressions but not current mood state or treatment status. Psychol Med 2002;32:251-8
4. MacQueen GM, Grof P. Alda M, et al. A pilot study of visual backward masking performance among affected versus unaffected offspring of parents with bipolar disorder. Bipolar Disord 2004;6:374-8
5. Thompson JM, Gallagher P, Hughes JH, et al. Neurocognitive impairment in euthymic patients with bipolar affective disorder. Br J Psychiatry 2005;186:32-40
6. Paradiso S, Lamberty GJ, Garvey MJ, et al. Cognitive impairment in the euthymic phase of chronic unipolar depression. J Nerv Ment Dis 1997;185:748-54
7. Beats BC, Sahakian BJ, Levy R. Cognitive performance in tests sensitive to frontal lobe dysfunction in the elderly depressed. Psychol Med 1996;26:591-603
8. Duman RS. Role of neurotrophic factors in the etiology and treatment of mood disorders. Neuromolecular Med 2004;5:11-25
9. Egan CG. Differentiation of hippocampal stem cells into functional neurons: evolving our understanding of monoamine oxidase-A inhibition. Br J Pharmacol 2006;148:563-4
10. Pettegrew JW, Levine J, McClure RJ. Acetyl-L-carnitine physical-chemical, metabolic, and therapeutic properties: relevance for its mode of action in Alzheimer's disease and geriatric depression. Mol Psychiatry 2000;5:616-32
11. Carnitine. The science behind a conditionally essential nutrient. Proceedings of a conference. March 25 - 26, 2004, Bethesda, Maryland, USA. Ann NY Acad Sci 2004;1033:ix-xi
12. Wolf G. The discovery of a vitamin role for carnitine: the first 50 years. J Nutr 2006;136:2131-4
13. Fraenkel G, Feiedman S. Carnitine. Vitam Horm 1957;15:73-118
14. Ziegler D, Hanefeld M, Ruhnau KJ, et al. Treatment of symptomatic diabetic polyneuropathy with the antioxidant α-lipoic acid: a 7-month multicenter randomized controlled trial (ALADIN III Study). ALADIN III Study Group. A-Lipoic Acid in Diabetic Neuropathy. Diabetes Care 1999;22:1296-301
15. Liu J, Atamna H, Kuratsune H, et al. Delaying brain mitochondrial decay and aging with mitochondrial antioxidants and metabolites. Ann NY Acad Sci 2002;959:133-66
16. Lin MT, Beal MF. Mitochondrial dysfunction and oxidative stress in neurodegenerative diseases. Nature 2006;443:787-95
17. Moreira PI, Santos MS, Seica R, et al. Brain mitochondrial dysfunction as a link between Alzheimer's disease and diabetes. J Neurol Sci 2007;257:206-14
18. Sauer J, Tabet N, Howard R. A lipoic acid for dementia. Cochrane Database Syst Rev 2004;1:CD004244
19. Coskun PE, Beal MF, Wallace DC. Alzheimer's brains harbor somatic mtDNA control-region mutations that suppress mitochondrial transcription and replication. Proc Natl Acad Sci USA 2004;101:10726-31
20. Vawter MP, Tomita H, Meng F, et al. Mitochondrial-related gene expression changes are sensitive to agonal-pH state: implications for brain disorders. Mol Psychiatry 2006;11:615,663-15,679
21. Iwamoto K, Bundo M, Kato T. Altered expression of mitochondria-related genes in postmortem brains of patients with bipolar disorder or schizophrenia, as revealed by large-scale DNA microarray analysis. Hum Mol Genet 2005;14:241-53
22. Konradi C, Eaton M, MacDonald ML, et al. Molecular evidence for mitochondrial dysfunction in bipolar disorder. Arch Gen Psychiatry 2004;61:300-8
23. Beasley CL, Pennington K, Behan A, et al. Proteomic analysis of the anterior cingulate cortex in the major psychiatric disorders: evidence for disease-associated changes. Proteomics 2006;6:3414-25
24. Droge W, Schipper HM. Oxidative stress and aberrant signaling in aging and cognitive decline. Aging Cell 2007;6:361-70
25. McIntyre RS, Soczynska JK, Woldeyohannes HO, et al. Thiazolidinediones: novel treatments for cognitive deficits in mood disorders? Expert Opin Pharmacother 2007;8:1615-28
26. Shea TB. Effects of dietary supplementation with N-acetyl cysteine, acetyl-L-carnitine and S-adenosyl methionine on cognitive performance and aggression in normal mice and mice expressing human ApoE4. Neuromolecular Med 2007;9:264-9
27. Ancelin ML, Christen Y, Ritchie K. Is antioxidant therapy a viable alternative for mild cognitive impairment? Examination of the evidence. Dement Geriatr Cogn Disord 2007;24:1-19
28. McIntyre RS, Soczynska JK, Woldeyohannes H, et al. Thiazolidinediones: from antioxidant to neurotherapeutic? Med Hypotheses 2007;69:773-7
29. Bremer J. Carnitine: metabolism and functions. Physiol Rev 1983;63:1420-80
30. Manoli I, De Martino MU, Kino T, et al. Modulatory effects of L-carnitine on glucocorticoid receptor activity. Ann NY Acad Sci 2004;1033:147-57
31. Kerner J, Hoppel C. Fatty acid import into mitochondria. Biochim Biophys Acta 2000;1486:1-17
32. Reda E, D'Iddio S, Nicolai R. et al. The carnitine system and body composition. Acta Diabetol 2003;40(Suppl 1):S106-13
33. Nalecz KA, Miecz D, Berezowski V, et al. Carnitine: transport and physiological functions in the brain. Mol Aspects Med 2004;25:551-67
34. Parnetti L, Gaiti A, Mecocci P, et al. Pharmacokinetics of IV and oral acetyl-L-carnitine in a multiple dose regimen in patients with senile dementia of Alzheimer type. Eur J Clin Pharmacol 1992;42:89-93
35. Liu J, Head E, Kuratsune H, et al. Comparison of the effects of L-carnitine and acetyl-L-carnitine on carnitine levels, ambulatory activity, and oxidative stress biomarkers in the brain of old rats. Ann NY Acad Sci 2004;1033:117-31
36. Luo Y, Packer L. Oxidative stress and age-related neurodegeneration. Boca Raton, FL: Taylor & Francis; 2006
37. Hagen TM, Ingersoll RT, Wehr CM, et al. Acetyl-L-carnitine fed to old rats partially restores mitochondrial function and ambulatory activity. Proc Natl Acad Sci USA 1998;95:9562-6
38. Dobbins RL, Szczepaniak LS, Bentley B, et al. Prolonged inhibition of muscle carnitine palmitoyltransferase-1 promotes intramyocellular lipid accumulation and insulin resistance in rats. Diabetes 2001;50:123-30
39. Ruderman NB, Saha AK, Vavvas D, et al. Malonyl-CoA, fuel sensing, and insulin resistance. Am J Physiol 1999;276:E1-18
40. Eaton S. Control of mitochondrial beta-oxidation flux. Prog Lipid Res 2002;41:107-239
41. McGarry JD. Travels with carnitine palmitoyltransferase I: from liver to germ cell with stops in between. Biochem Soc Trans 2001;29:241-5
42. Stephens FB, Constantin-Teodosiu D, Laithwaite D, et al. Insulin stimulates L-carnitine accumulation in human skeletal muscle. FASEB J 2006;20:377-9
43. Famularo G, De Simone C, Trinchieti V, et al. Carnitines and its congeners: a metabolic pathway to the regulation of immune response and inflammation. Ann NY Acad Sci 2004;1033:132-8
44. Heo YR, Kang CW, Cha YS. L-Carnitine changes the levels of insulin-like growth factors (IGFs) and IGF binding proteins in streptozotocin-induced diabetic rat. J Nutr Sci Vitaminol (Tokyo) 2001;47:329-34
45. Hino K, Nishikawa M, Sato E, et al. L-carnitine inhibits hypoglycemia-induced brain damage in the rat. Brain Res 2005;1053:77-87
46. Foster DW. The role of the carnitine system in human metabolism. Ann NY Acad Sci 2004;1033:1-16
47. Abdul HM, Calabrese V, Calvard M, et al. Acetyl-L-carnitine-induced up-regulation of heat shock proteins protects cortical neurons against amyloid-beta peptide 1-42-mediated oxidative stress and neurotoxicity: implications for Alzheimer's disease. J Neurosci Res 2006;84:398-408
48. Calabrese V, Giuffida Stella AM, Calvani M, et al. Acetylcarnitine and cellular stress response: ables in nutritional redox homeostesis and regulation of longevity genes. J Nutr Biochem 2006;17:73-88
49. Kaur J, Sharma D, Singh R. Acetyl-L-carnitine enhances Na(+), K(+)-ATPase glutathione-S-transferase and multiple unit activity and reduces lipid peroxidation and lipofuscin concentration in aged rat brain regions. Neurosci Lett 2001;301:1-4
50. Calvani M, Arrigoni-Martelli E. Attenuation by acetyl-L-carnitine of neurological damage and biochemical derangement following brain ischemia and reperfusion. Int J Tissue React 1999;21:1-6
51. Pascale A, Milano S, Corsico N, et al. Protein kinase C activation and anti-amnesic effect of acetyl-L-carnitine: in vitro and in vivo studies. Eur J Pharmacol 1994;65:1-7
52. Mosser DD, Morimoto RI. Molecular chaperones and the stress of oncogenesis. Oncogene 2004;23:2907-18
53. Haddad JJ , Saade NE, Safieh-Garabedian B. Cytokines and neuro-immune-endocrine interactions: a role for the hypothalamic-pituitary-adrenal revolving axis. J Neuroimmunol 2002;133:1-19
54. Ghirardi O, Caprioli A, Ramacci MT, et al. Effect of long-term acetyl-L-carnitine on stress-induced analgesia in the aging rat. Exp Gerontol 1994;29:569-74
55. Izgut-Uysal VN, Agac A, Derin N. Effect of L-carnitine on carrageenan-induced inflammation in aged rats. Gerontology 2003;49:287-92
56. Winter BK, Fiskum G, Gallo LL. Effects of L-carnitine on serum triglyceride and cytokine levels in rat models of cachexia and septic shock. Br J Cancer 1995;72:1173-9
57. Thal LJ, Carta A, Clarke WR, et al. A 1-year multicenter placebo-controlled study of acetyl-L-carnitine in patients with Alzheimer's disease. Neurology 1996;47:705-11.
58. Brooks JO III, Yesavage JA, Carta A, et al. Acetyl L-carnitine slows decline in younger patients with Alzheimer's disease: a reanalysis of a double-blind, placebo-controlled study using the trilinear approach. Int Psychogeriatr 1998;10:193-203
59. Pettegrew JW, Levine J, Gershon S, et al. 31P-MRS study of acetyrl-L-carnitine treatment in geriatric depression: preliminary results. Bipolar Disord 2002;4:61-6
60. Garzya G, Corallo, D, Fiore A, et al. Evaluation of the effects of L-acetylcarnitine on senile patients suffering from depression. Drugs Exp Clin Res 1990;16:101-6
61. Gecele M, Francesetti G, Meluzzi A. Acetyl-L-Carnitine in aged subjects with major depression: clinical efficacy and effects on the circadian rhythm of cortisol. Dement Geriatr Cogn Disord 1991;2:333-7
62. Fulgente T, Onofrj M, Del Re MI, et al. Laevo-acetylcarnitine (Nicetile registered) treatment of senile depression. Clin Trials J 1990;27:155-63
63. Pettegrew JW, Klunk WE, Panchalingam K, et al. Clinical and neurochemical effects of acetyl-L-carnitine in Alzheimer's disease. Neurobiol Aging 1995;16:1-4
64. Bast A, Hachen GR. Lipoic acid: a multifunctional antioxidant. Biofactors 2003;17:207-13
65. Reed LJ, DeBusk BG, Gunsalus IC, et al. Crystalline α-lipoic acid; a catalytic agent associated with pyruvate dehydrogenase. Science 1951;114:93-4
66. Fuchs J, Packer L, Zimmer G. Lipoic acid in health and disease. New York: Marcel Dekker, Inc.; 1997
67. Andreassen OA, Ferrante RJ, Dedeoglu A, et al. Lipoic acid improves survival in transgenic mouse models of Huntington's disease. Neuroreport 2001;12:3371-3
68. Holmquist L, Stuchbury G, Berbaum K, et al. Lipoic acid as a novel treatment for Alzheimer's disease and related dementias. Pharmacol Ther 2007;113:154-64
69. Sharma M, Gupta YK. Effect of α lipoic acid on intracerebroventricular streptozotocin model of cognitive impairment in rats. Eur Neuropsychopharmacol 2003;13:241-7
70. Packer L, Witt EH, Tritschler HJ. α-Lipoic acid as a biological antioxidant. FreeRadic Biol Med 1995;19:227-50
71. Estrada DE, Ewart HS, Tsakiridis T, et al. Stimulation of glucose uptake by the natural coenzyme α-lipoic acid/thioctic acid: participation of elements of the insulin signaling pathway. Diabetes 1996;45:1798-804
72. Frolich L, Gotz ME, Weinmuller M, et al. (r)-, but not (s)-α lipoic acid stimulates deficient brain pyruvate dehydrogenase complex in vascular dementia, but not in Alzheimer dementia. J Neural Transm 2004;111:295-310
73. Devasagayam TP, Di Mascio P, Kaiser S, et al. Singlet oxygen induced single-strand breaks in plasmid pBR322 DNA: the enhancing effect of thiols. Biochim Biophys Acta 1991;1088:409-12
74. Gross SS, Wolin MS. Nitric oxide: pathophysiological mechanisms. Ann Rev Physiol 1995;57:737-69
75. Suzuki YJ, Tsuchiya M, Parker L. Thioctic acid and dihydrolipoic acid are novel antioxidants which interact with reactive oxygen species. Free Radic Res Commun 1991;15:255-63
76. Giedzinski E, Rola R, Fike JR, et al. Efficient production of reactive oxygen species in neural precursor cells after exposure to 250 MeV protons. Radiat Res 2005;164:540-4
77. Marracci GH, McKeon GP, Marquardt WE, et al. α lipoic acid inhibits human T-cell migration: implications for multiple sclerosis. J Neurosci Res 2004;78:362-70
78. McIntyre RS, Soczynska JK, Lewis GF, et al. Managing psychiatric disorders with antidiabetic agents: translational research and treatment opportunities. Expert Opin Pharmacother 2006;7:1305-21
79. Quinn JF, Bussiere JR, Hammond RS, et al. Chronic dietary α-lipoic acid reduces deficits in hippocampal memory of aged Tg2576 mice. Neurobiol Aging 2007;28:213-25
80. Stoll S, Hartmann H, Cohen SA, et al. The potent free radical scavenger α-lipoic acid improves memory in aged mice: putative relationship to NMDA receptor deficits. Pharmacol Biochem Behav 1993;46:799-805
81. Poon HF, Farr SA, Thongboonkerd V, et al. Proteomic analysis of specific brain proteins in aged SAMP8 mice treated with α-lipoic acid: implications for aging and age-related neurodegenerative disorders. Neurochem Int 2005;46:159-68
82. Farr SA, Poon HF, Dogrukol-Ak D, et al. The antioxidants α-lipoic acid and N-acetylcysteine reverse memory impairment and brain oxidative stress in aged SAMP8 mice. J Neurochem 2003;84:1173-83
83. Hagen TM, Ingersoll RT, Lykkesfeldt J, et al. (R)-α-lipoic acid-supplemented old rats have improved mitochondrial function, decreased oxidative damage, and increased metabolic rate. FASEB J 1999;13:411-8
84. Hager K, Marahrens A, Kenklies M, et al. A-lipoic acid as a new treatment option for Azheimer type dementia. Arch Gerontol Geriatr 2001;32:275-82
85. Dana Consortium on the Therapy of HIV Dementia and Related Cognitive Disorders. A randomized, double-blind, placebo-controlled trial of deprenyl and thioctic acid in human immunodeficiency virus-associated cognitive impairment. Neurology 1998;50:645-51
86. Salazar MR. A lipoic acid: a novel treatmeric for depression. Med Hypotheses 2000;55:510-2
87. Ames BN, Liu J. Delaying the mitochondrial decay of aging with acetylcarnitine. Ann NY Acad Sci 2004;1033:108-16
88. Liu J, Head E, Gharib AM, et al. Memory loss in old rats is associated with brain mitochondrial decay and RNA/DNA oxidation: partial reversal by feeding acetyl-L-carnitine and/or R-α-lipoic add. Proc Natl Acad Sci USA 2002;99:2356-61
89. Muthuswamy AD, Vedagiri K, Ganesan M, et al. Oxidative stress-mediated macromolecular damage and dwindle in antioxidant status in aged rat brain regions: role of L-carnitine and DL-Iipoic acid. Clin Chim Acta 2006;368:84-92
90. Milgram NW, Head E, Zicker SC, et al. Long-term treatment with antioxidants and a program of behavioral enrichment reduces age-dependent impairment in discrimination and reversal learning in beagle dogs. Exp Gerontol 2004;39:753-65
91. Ando S, Tadenuma T, Tanaka Y, et al. Enhancement of learning capacity and cholinergic synaptic function by carnitine in aging rats. J Neurosci Res 2001;66:266-71
92. Thal LJ, Calvani M, Amato A, Carta A. A 1-year controlled trial of acetyl-l-carnitine in early-onset AD. Neurology 2000;55:805-10
93. Pettegrew JW, Klunk WE, Panchalingam K, et al. Clinical and neurochemical effects of acetyl-L-carnitine in Alzheimer's disease. Neurobiol Aging 1995;16:1-4
94. Spagnoli A, Lucca U, Menasce G, et al. Long-term acetyl-L-carnitine treatment in Alzheimer's disease. Neurology 1991;41:1726-32
95. Zanardi R, Smeraldi E. A double-blind, randomised, controlled clinical trial of acecyl-L-carnitine vs. amisulpridc in the treatment of dysthymia. Eur Neuropsychopharmacol 2006;16:281-7
96. Bella R, Biondi R, Raffaele R, et al. Effect of acetyl-L-carnitine on geriatric patients suffering from dysthymic disorders. Int J Clin Pharmacol Res 1990;10:355-60
97. Nasca D, Zurria G, Aguglia E. Actions of acetyl-l-carnitine in association with mianserine on depressed old people. New Trends Clin Neuropharmacol 1989;3:225-30
98. De Simone C, Catania S, Trinchieri V, et al. Amelioration of the depression of HIV-infected subjects with L-acetyl carnitine therapy. J Drug Dev 1988;3:163-6
99. Tempesta E, Casella L, Pirrongelli C, et al. L-acetylcarnitine in depressed elderly subjects. A cross-over study vs placebo. Drugs Exp Clin Res 1987;13:417-23
100. Villardita C, Smirni P, Vecchio I. Acetyl-l-carnitine in depressed geriatric patients. European review for medical and pharmacological sciences 1983;6:1-12
101. Biessels GJ, Smale S, Duis SE, et al. The effect of gamma-linolenic acid-α-lipoic acid on functional deficits in the peripheral and central nervous system of streptozotocin-diabetic rats. J Neurol Sci 2001;182:99-106
102. Hudson S, Tabet N. Acetyl-L-carnitine for dementia. Cochrane Database Syst Rev 2003;(2):CD003158
103. Montgomery SA, Thal LJ, Amrein R. Meta-analysis of double blind randomized controlled clinical trials of acetyl-L-carnitine versus placebo in the treatment of mild cognitive impairment and mild Alzheimer's disease. Int Clin Psychopharmacol 2003;18(2):61-71